Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TECHNIVIE vs ANEXSIA 7.5/650
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Technivie is a fixed-dose combination of ombitasvir, paritaprevir, and ritonavir. Ombitasvir is an NS5A inhibitor that inhibits HCV RNA replication and virion assembly. Paritaprevir is an NS3/4A serine protease inhibitor that prevents cleavage of the HCV polyprotein. Ritonavir is a pharmacokinetic enhancer that inhibits CYP3A-mediated metabolism of paritaprevir, increasing its plasma levels.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
Treatment of chronic hepatitis C virus (HCV) genotype 4 infection in adult patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) in combination with ribavirin
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
TECHNIVIE (ombitasvir, paritaprevir, and ritonavir) is administered orally as two fixed-dose combination tablets (each containing ombitasvir 12.5 mg, paritaprevir 75 mg, and ritonavir 50 mg) taken once daily in the morning with food, in combination with dasabuvir (250 mg twice daily with food) for genotype 1b or with ribavirin for genotype 1a.
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
Terminal half-life approximately 40 hours, supporting once-daily dosing
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Ombitasvir: Primarily metabolized by amide hydrolysis followed by oxidative metabolism. Paritaprevir: Primarily metabolized by CYP3A4. Ritonavir: Primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6.
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Biliary/fecal (majority, >90% as unchanged drug); renal (<1%)
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
>99.9%, primarily to albumin and alpha-1-acid glycoprotein
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
0.2 L/kg, indicating distribution largely confined to plasma and extracellular fluid
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
Oral: not determined; absorption is rapid with Tmax of 4-5 hours post-dose
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
No dose adjustment of TECHNIVIE is required for patients with any degree of renal impairment, including those on dialysis. However, if used with ribavirin, refer to ribavirin dosing adjustments for renal impairment.
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
TECHNIVIE is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). No dose adjustment is needed for mild hepatic impairment (Child-Pugh class A).
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
Safety and efficacy in pediatric patients below 18 years of age have not been established; therefore, no dosing recommendations are available.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
No dose adjustment of TECHNIVIE is required in elderly patients. Clinical studies included patients aged 65 and older, with no overall differences in safety or efficacy observed.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
Boxed Warning: Risk of Hepatitis B Virus (HBV) Reactivation. HBV reactivation has been reported in patients co-infected with HCV and HBV who were treated with direct-acting antivirals for HCV. Some cases resulted in fulminant hepatitis, hepatic failure, and death. Test all patients for evidence of current or prior HBV infection before starting Technivie. Monitor patients for HBV reactivation during treatment and post-treatment follow-up.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
HBV reactivation: Screen for HBV before initiation.,Hepatic decompensation/hepatic failure in patients with cirrhosis: Discontinue if signs of hepatic decompensation occur.,Increases in transaminases: Monitor hepatic function, especially during first 4 weeks of therapy.,Use with estrogen-containing contraceptives: May increase ALT levels; discontinue estrogens if ALT elevation occurs.,Drug interactions: Technivie is a CYP3A4 inhibitor; consider dose adjustments of sensitive CYP3A4 substrates.,Ribavirin: Use with caution in patients with creatinine clearance <50 m L/min.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
Severe hepatic impairment (Child-Pugh B or C) or decompensated cirrhosis.,Concomitant use with drugs that are strong CYP3A inducers (e.g., rifampin, St. John's wort).,Known hypersensitivity to ombitasvir, paritaprevir, ritonavir, or any excipients.,Concomitant use with drugs highly dependent on CYP3A for clearance (e.g., alfuzosin, ergot derivatives, lovastatin, simvastatin, etc.).,Concomitant use with ethinyl estradiol-containing contraceptives.
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
Take with food to increase absorption (increase paritaprevir exposure). No specific dietary restrictions. Avoid grapefruit products? Not reported for TECHNIVIE, but ritonavir has interactions with grapefruit; generally not recommended due to potential CYP3A4 interaction.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
Insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Avoid in pregnancy unless benefit outweighs risk.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
No data on presence in human milk; risk to infant cannot be excluded. M/P ratio unknown.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
No dose adjustment required based on pharmacokinetic changes in pregnancy; monitor closely.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
TECHNIVIE (ombitasvir/paritaprevir/ritonavir) is indicated for chronic hepatitis C genotype 4 without cirrhosis or with compensated cirrhosis (Child-Pugh A). Avoid in decompensated cirrhosis (Child-Pugh B or C) due to risk of hepatic decompensation. Ritonavir is a strong CYP3A4 inhibitor; check for drug interactions. Monitor hepatic function closely, especially in patients with cirrhosis.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Take with food to improve absorption and reduce gastrointestinal side effects.,Do not stop taking this medication without consulting your doctor.,Inform your doctor of all medications you take, including over-the-counter and herbal supplements, due to significant drug interactions.,Report symptoms of liver problems: yellowing of skin/eyes, dark urine, abdominal pain, or nausea/vomiting.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TECHNIVIE vs ANEXSIA 7.5/650, answered by our medical review team.
TECHNIVIE is a Direct-acting antiviral that works by Technivie is a fixed-dose combination of ombitasvir, paritaprevir, and ritonavir. Ombitasvir is an NS5A inhibitor that inhibits HCV RNA replication and virion assembly. Paritaprevir is an NS3/4A serine protease inhibitor that prevents cleavage of the HCV polyprotein. Ritonavir is a pharmacokinetic enhancer that inhibits CYP3A-mediated metabolism of paritaprevir, increasing its plasma levels.. ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TECHNIVIE and ANEXSIA 7.5/650 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TECHNIVIE is: TECHNIVIE (ombitasvir, paritaprevir, and ritonavir) is administered orally as two fixed-dose combination tablets (each containing ombitasvir 12.5 mg, paritaprevir 75 mg, and ritonavir 50 mg) taken once daily in the morning with food, in combination with dasabuvir (250 mg twice daily with food) for genotype 1b or with ribavirin for genotype 1a.. The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TECHNIVIE and ANEXSIA 7.5/650 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TECHNIVIE is classified as Category C. Insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Avoid in pregnancy unless benefit outweighs risk.. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.